Солитарная (экстрамедуллярная) плазмоцитома

1. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12): e538–e548.
2. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015; 20 (3): 413–22.
3. Lewis EB. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists. Science 1963; 142 (3598): 1492–4.
4. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res 1987; 47 (11): 2978–81.
5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91 (1): 3–21.
6. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) 2017.
7. Caers J et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018; 11 (1): 10.
8. Grammatico S, Scalzulli E, Petrucci MT. Solitary Plasmacytoma. Mediterr J Hematol Infect Dis 2017; 9 (91): 1–14.
9. Guo SQ et al. Prognostic factors associated with solitary plasmacytoma. Onco Targets Ther 2013; 6: 1659–66.
10. Вотякова О.М., Менделеева Л.П. Солитарная плазмоцитома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М., 2018; с. 302–7.
[Votyakova O.M., Mendeleev L.P. Solitary plasmacytoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Moscow, 2018; p. 302–7 (in Russian).]
11. Wilder RB et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002; 94 (5): 1532–7.
12. Thakar YS et al. Immunochemical studies in multiple myeloma. Indian J Cancer 1997; 34 (4): 151–8.
13. Hill QA et al. Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood 2014; 124 (8): 1296–9.
14. Dingli D et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108 (6): 1979–83.
15. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М., 2018; с. 213–41.
[Mendeleev L.P., Votyakova O.M., Rekhtina I.G. Multiple myeloma Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Moscow, 2018; p. 213–41 (in Russian).]
16. Zamagni E et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92 (1): 50–5.
17. Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol 2003; 24 (6): 395–9.
18. Tsang RW et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101 (4): 794–808.
19. Tsang RW et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001; 50 (1): 113–20.
20. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
21. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

________________________________________________

1. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12): e538–e548.
2. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015; 20 (3): 413–22.
3. Lewis EB. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists. Science 1963; 142 (3598): 1492–4.
4. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res 1987; 47 (11): 2978–81.
5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91 (1): 3–21.
6. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) 2017.
7. Caers J et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018; 11 (1): 10.
8. Grammatico S, Scalzulli E, Petrucci MT. Solitary Plasmacytoma. Mediterr J Hematol Infect Dis 2017; 9 (91): 1–14.
9. Guo SQ et al. Prognostic factors associated with solitary plasmacytoma. Onco Targets Ther 2013; 6: 1659–66.
10. Votyakova O.M., Mendeleev L.P. Solitary plasmacytoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Moscow, 2018; p. 302–7 (in Russian).
11. Wilder RB et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002; 94 (5): 1532–7.
12. Thakar YS et al. Immunochemical studies in multiple myeloma. Indian J Cancer 1997; 34 (4): 151–8.
13. Hill QA et al. Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood 2014; 124 (8): 1296–9.
14. Dingli D et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108 (6): 1979–83.
15. Mendeleev L.P., Votyakova O.M., Rekhtina I.G. Multiple myeloma Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Moscow, 2018; p. 213–41 (in Russian).
16. Zamagni E et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92 (1): 50–5.
17. Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol 2003; 24 (6): 395–9.
18. Tsang RW et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101 (4): 794–808.
19. Tsang RW et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001; 50 (1): 113–20.
20. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
21. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

Н.А. Фалалеева1, А.Ю. Терехова1, В.В. Птушкин2, Е.А. Османов3,4, И.В. Поддубная5, А.А. Невольских1, С.А. Иванов1, Ж.В. Хайлова1, Т.Г. Геворкян3

1 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия;
2 ГБУЗ «Городская клиническая больница им. С.П. Боткина», Москва, Россия;
3 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
4 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
5 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия

________________________________________________

Natal'ia A. Falaleeva1, Alena Iu. Terekhova1, Vadim V. Ptushkin2, Evgenii A. Osmanov3,4, Irina V. Poddubnaya5, Aleksei A. Nevol'skikh1, Sergei A. Ivanov1, Zhanna V. Khailova1, Tigran G. Gevorkian3

1 Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology, Moscow, Russia;
2 Botkin City Clinical Hospital, Moscow, Russia;
3 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
5 Russian Medical Academy of Continuous Professional Education, Moscow, Russia